ABSTRACT
Adjuvant laser therapy of vascular anomalies is based on the principle of selective photo‐thermolysis, through targeted destruction of selected chromophores with minimal injury to surrounding tissue. Choice of laser wavelength, treatment parameters, and predicted response to therapy are dependent on the dominant chromophore within the vascular anomaly, lesional location, and target depth, with relatively superficial and mucosal lesions producing the best response to therapy. Lasers can be safely combined with multi‐modal approaches for vascular anomalies, including sclerotherapy, surgical excision, and systemic therapy. In this manuscript, we review the laser literature on a range of vascular anomalies, and provide indications, appropriate therapeutic and warning endpoints in the skin, pearls/pitfalls, and multi‐disciplinary approaches for pediatric dermatologists pursuing laser as adjuvant therapy for vascular anomalies.
Keywords: arteriovenous malformations, laser, lymphatic abnormalities, vascular malformation
1. Introduction
Vascular anomalies (VA) are a diverse set of disorders that cumulatively affect 7–8% of the population, represent developmental disorders of the vasculature, and range from vascular staining of the skin to debilitating overgrowth, tumors, and abnormalities of soft tissue, bone, muscle, brain, and eye [1]. These lesions are slowly progressive, cosmetically disfiguring, and may be associated with life‐threatening, multi‐organ disease. Over time, they can impact quality of life, emotional wellbeing, and peer relationships. Gene discovery in the last decade has mapped ~90% of VAs to activating mosaic pathogenic variants in genes along the MAP kinase signaling pathway (Table 1) [12, 13]. In part due to disease heterogeneity, uniform guidelines for patients with VAs are lacking, and a variety of treatments ranging from active nonintervention to sclerotherapy, surgical excision, medical, and laser surgery are utilized in management, optimally in a multi‐disciplinary approach.
TABLE 1.
Somatic and germline variants implicated in vascular anomalies/vascular anomaly syndromes.
| Vascular anomaly | Somatic variant | Inherited variant |
|---|---|---|
| LM | Single gene changes in PIK3CA reported in approximately 80% of LMs on biopsy [2]. PIK3CA mutations shown with Droplet Digital PCR (ddPCR) on lymphatic fluid [3, 4]. | None. |
| VM |
Somatic variants in TEK (TIE2 receptor) or PIK3CA genes [5] PI3K/AKT pathway, downstream to the TIE2 receptor, may also be a factor. Blue rubber bleb nevus syndrome, a rare disorder involving innumerable VMs in the skin and viscera, particularly the gut, has also been mapped to double hit mosaic activating variants in TEK [6]. |
Multi‐focal VMs can rarely be inherited via germline variants in TEK and may also be mapped to mosaic double (cis) mutations, with two somatic TEK mutations on the same allele of the gene. |
| GVM | Second hit somatic variants in glomulin drive the clinical phenotype in tissue [7]. | Most GVMs harbor autosomal dominant variants in the glomulin gene [7]. The development of GVMs in tissue is felt to occur when this germline variant is coupled to a “2nd hit” somatic variant in affected tissue, underlying the multifocal phenotype of disease in the skin. |
| AVM |
Most AVMs are mosaic, with MAP2K1 mutations seen in > 50% extracranial AVM patients, whereas KRAS and BRAF mutations were identified in 80%–100% of brain and spinal AVM patients [8, 9]. Variants in RASA1 and EPHB4 can occur via both somatic hits and autosomal dominant germline inheritance. |
Autosomal dominant variants in RASA1 and EPHB4 induce CM‐AVM syndrome. RASA1 variants induce 50%–70% of CM‐AVM1, whereas EPHB4 mutations are seen in the recently described phenotype CM‐AVM2 [10]. |
| VVM | Genetics of VVMs are incompletely understood. Somatic variants in KRIT1 may also occur. Activating somatic MAP3K3 variants have been demonstrated in some patients [11]. | Some VVMs are associated with germline variants in KRIT1. |
Since the 1980s, when Anderson and Parrish defined the concept of selective photothermolysis, lasers have found widespread use in dermatology [14]. Development of millisecond (ms)‐pulsed dye lasers enabled selective photocoagulation in VA, utilizing laser wavelengths that selectively target oxygenated and deoxygenated hemoglobin. Laser treatment is considered standard of care for simple capillary malformations or port wine birthmarks (PWBs), which have been well described elsewhere and are beyond the scope of this review [15, 16]. In contrast, complex VAs pose both opportunities and challenges in laser therapy. For extensive lesions or those with significant lesional depth, laser is rarely considered as monotherapy. Here, we summarize the existing literature on laser as adjuvant therapy for the treatment of lymphatic, venous, glomuvenous, arteriovenous, and verrucous venous malformations (VVMs) using PubMed and Web of Science databases. Randomized control trials (RCT), retrospective reviews (RR), prospective interventional studies, and case series with ≥ 3 adult and pediatric patients were included for both cutaneous and mucosal VAs (Figure 1). Due to limited evidence‐based literature across all VAs, the authors also provide indications, pearls, pitfalls, and multi‐disciplinary approaches for the pediatric dermatologist in considering laser as adjuvant therapy for VA.
FIGURE 1.

PRISMA diagram depicting removal of same reports from the two different databases and after application of our inclusion criteria.
2. Background
Using the principle of selective photothermolysis [14], light absorbing chromophores can be selectively targeted, heated, and damaged or destroyed with minimal injury to surrounding structures. VA chromophores and corresponding laser wavelengths (based on the dominant chromophore and depth) are listed in Table 2. VAs can be low‐flow (venous), high‐flow (arterial), or mixed. Deoxygenated (venous) and oxygenated (arterial) hemoglobin have different absorption curves.
TABLE 2.
Laser targets in vascular anomalies.
| Vascular anomaly [17] | Chromophore [17] | Peak absorption (nm) | Laser wavelength choices [17] | Depth of laser target (in mm) |
|---|---|---|---|---|
| Lymphatic malformation | Water | 2940, 10,600 | Erbium:YAG | 1–2 a |
| CO2 | 2 b | |||
| Venous malformation | Deoxyhemoglobin | 750–800 | Lp alexandrite | 3–4 |
| Lp Nd:YAG | 4–5 | |||
| Glomuvenous malformation | Deoxyhemoglobin | 750–800 | Lp alexandrite | 3–4 |
| Lp Nd:YAG | 4–5 | |||
| Arteriovenous malformation | Oxy‐ and deoxyhemoglobin | 418, 542, 577 for oxy‐hemoglobin 750–800 for deoxyhemoglobin | PDL | ≤ 1 |
| Ruby | 3 | |||
| Lp alexandrite | 3–4 | |||
| Lp Nd:YAG | 4–5 | |||
| Erbium:YAG | 1–2 a | |||
| Verrucous venous malformations | Water and deoxyhemoglobin | 750–800, 2940, 10,600 | CO2 | 2 b |
| Lp alexandrite | 3–4 | |||
| Lp Nd:YAG | 4–5 |
Depth of penetration from the Erbium YAG can be extended with multiple passes.
Depth of penetration from the CO2 laser can be extended with multiple passes.
When treating VAs with laser, three elements are necessary to achieve a clinical effect. First, the chosen wavelength must be preferentially absorbed by the target and must propagate to the target depth. For complex VAs with multiple chromophores, the dominant chromophore is targeted. Clinical morphology can be useful in this calculus. For example, venolymphatic malformations (LMs) with predominantly microcystic lymphatic blebs at the epidermal surface are best treated using wavelengths targeting water (Erbium or CO2), whereas long‐pulsed (Lp) alexandrite, Lp neodymium‐doped yttrium aluminum garnet (Nd:YAG) lasers, or sclerotherapy would be better choices for predominantly venous components. Color may also offer clues to the dominant chromophore, with most bluish or purple VAs corresponding to deoxygenated venous blood, and those that are pink or various shades of red corresponding to arterial or capillary blood (see Figure 2). In complex VAs with predominantly subcutaneous involvement, lesional depth should be assessed, with consideration of quantitative imaging modalities including ultrasound or MRI/MRA with/without contrast. Imaging is critical not just for the selection of the appropriate laser wavelength, but to determine whether laser should be considered as a primary treatment modality. Treatment of lesions with > 5–6 mm depth [18], the likely limit of penetration for longer penetrating infrared lasers including Lp Nd:YAG, should be combined with other modalities, including sclerotherapy, embolization, surgery, or medical treatments to target deeper components.
FIGURE 2.

Images of LM (a, b), VM (c, d), and GVM (e, f) pre/post‐treatment. Macrocystic/microcystic LM (a) on the abdomen and, (b) response following one session of bleomycin sclerotherapy followed by ablative fractional CO2 with multiple passes. Venous malformation (c) on the lower lip and (d) after four sessions of Lp Nd:YAG laser. Multi focal (e) glomuvenous malformations on the back and (f) after one treatment with Lp Nd:YAG laser.
Second, for all wavelengths not targeting water as the chromophore, the pulse duration (PD) should be less than or equal to the target thermal relaxation time (TRT). In ms, this approximates the square root of the vessel diameter in micrometers (μm), thereby facilitating target selectivity while protecting surrounding tissue from overheating. PWB vessel diameters range from 10 to 300 μm, with optimal PD thus ranging from 1 to 10 ms. Glomuvenous, arteriovenous, and venous malformations (VMs) have larger vessels based on histopathology, suggesting that PDs should be longer than for PWBs, as they will have a longer TRT based on vessel size. Most VAs are likely to be heterogeneous in vessel diameter, and thus initial laser settings should be chosen conservatively, particularly for longer wavelength lasers due to the higher risk for scarring associated with deeper penetration.
Finally, sufficient fluence (energy per unit area) must be emitted to damage target vessels while minimizing collateral tissue damage. In VAs composed of smaller diameter vessels, photocoagulation occurs, hemoglobin is heated, and denaturation of vessel walls occurs, ideally resulting in lesional clearance. In contrast, laser treatment of larger diameter VAs may not produce destruction of the vessel wall but may instead induce vessel collapse due to ejection of the heated hemoglobin. In this way, laser can be thought of as a form of superficial sclerotherapy, in which vessels collapse and scar centrally like a flattened pancake. In addition, laser light produces photocoagulation within the vasculature, resulting in secondary damage to the vessel wall, which diminishes or eliminates flow, leading to resorption of the target vessel. Theoretically, these laser‐tissue interactions lead to VA improvement.
3. Lymphatic Malformations
LMs are low‐flow, infiltrating, and congenital abnormalities of lymphatic vessels and can consist of predominantly macrocysts (> 1 cm), predominantly microcysts (< 1 cm), or a combination. LMs can occur anywhere in the body; commonly seen in the head/neck (75%–80%) and axilla (20%) [19]. Occasionally, LMs are diagnosed prenatally with ultrasound but are more commonly observed within the first few years of life [19]. Extensive LMs are most amenable to targeted medical therapy with alpelisib (direct PiK3CA inhibitor) and sirolimus (mTOR inhibition). Macrocystic LMs are most amenable to sclerotherapy with doxycycline, bleomycin, or sodium sotradecol by interventional radiology (IR). Microcystic LMs are more difficult to treat from an interventional approach but may respond to interstitial bleomycin or laser, or medical therapy with sirolimus. However, microcystic LMs are highly prone to recurrence regardless of the treatment modality [19, 20].
In this review, the literature on laser treatment of LMs was sparse: Five case series and four RR met the inclusion/exclusion criteria (Table 3) [21, 22, 23, 24, 25, 26, 27, 28, 29]. RCT and prospective studies with rigorous statistical analysis were lacking. There were no cutaneous LMs that met study inclusion criteria, and all series involved LMs of the oral cavity. Intraoral LMs involving the tongue and oral cavity are primarily managed by otorhinolaryngology, and therefore we include only our pearls/pitfalls for cutaneous LMs below.
TABLE 3.
Lymphatic malformation laser treatment and parameters.
| Laser type | Wavelength | Power/fluence | Spot size | Pulse duration | Patients treated |
|---|---|---|---|---|---|
| CO2 [21] | 10,600 nm | 114.65–191.02 J/cm2 | N/A | N/A | 17 |
| CO2 continuous discharge mode [22] | 10,600 nm | 15–25 W, 480–780 W/cm2 | 2 mm | N/A | 7 |
| CO2 continuous or intermittent mode [23] | 10,600 nm | 5–15 W | N/A | N/A | 4 |
| Lp Nd:YAG CW12 | 1064 nm | 20‐40 W | N/A | 500–1000 ms | 5 |
| Diode [24] | 900 nm | 90–100 J/cm2 | N/A | N/A | 6 |
| CO2 [25] | N/A | 5 W | 2 mm | N/A | 3 |
| CO2, Lp Nd:YAG, KTP, PDL [26] | N/A | N/A | N/A | N/A | 22 |
| CO2 [27] | N/A | 2–4, 8–15 W | < 0.3 mm | N/A | 20 |
| KTP [28] | N/A | N/A | N/A | N/A | 3 |
| CO2 [29] | N/A | 30 W | 6 mm | N/A | 26 |
3.1. Author Pearls/Pitfalls
In our collective experience, LMs with a microcystic component involving the skin can be safely treated with laser wavelengths that appropriately target water (either Erbium:YAG or CO2), with either an ablative fractional or purely ablative handpiece. In general, settings should be tailored to the endpoint of removal of the superficial vesicles and blebs. If an ablative fractionated handpiece is used, then higher density settings (in the range of 20%–30% fractionation), with several passes over the tissue and gentle curettage of the vesicles, are sufficient to remove the visible portion of the LM. Erbium laser may be best utilized with coagulation off, as hemostasis is rarely required, with limited surrounding tissue vaporization. Curettage through the superficial dermis may lead to an increased risk of scarring but also less recurrence over time (scar may replace the VA). In our collective experience, these treatments can be safely combined with sclerotherapy in the same session, with IR targeting deeper components and laser targeting more superficial components. This has not been extensively investigated in the literature but may produce more durable responses by targeting the deeper component in the LM. For superficial microcystic LMs, topical sirolimus is currently under investigation in clinical trials, but individual case reports demonstrate improvement in symptoms and lesional size [30, 31]. Patients on systemic therapy with sirolimus or alpelisib are at potentially higher risk for poor wound healing [32]. We suggest individualized patient screening to temporarily discontinue medical therapy, if feasible, to minimize laser therapy risk.
4. Venous Malformations
With an incidence of approximately 1 in every 2000–5000 individuals, VMs are relatively common [33] and have been mapped to activating somatic variants in the TEK (TIE2 receptor) or PIK3CA genes (Table 1) [34]. In this review, a total of 16 case series and 9 retrospective cohort studies of VMs treated with laser met our inclusion/exclusion criteria (Table 4) [18, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57]. As in LMs, the quality of the evidence was overall low.
TABLE 4.
Venous malformation laser type and parameters.
| Laser type | Wavelength | Power/fluence | Spot size | Pulse duration | Patients treated |
|---|---|---|---|---|---|
| Lp Nd:YAG [18] | 1064 nm | 90.7 J/cm2 | N/A | N/A | 138 |
| CO2 [34] | 10,600 nm | 2 W/cm2 | N/A | N/A | 5 |
| Nd:YAG [35] | 1064 nm | 80–100 J | 8–12 mm | 50 ms | 59 |
| CW Nd:YAG, Lp Nd:YAG [36] | 1064 nm (CW Nd:YAG) | 20–25 W | N/A | 1–2/s | 56 |
| 1064 nm (Lp Nd:YAG) | 250 J/cm2 | 3 mm | 10 ms | ||
| Lp Nd:YAG [37] | 1064 nm | 20–30 W | N/A | 500–1000 ms | 32 |
| Lp Nd:YAG [38] | 1064 nm | 60–120 J/cm2 | 7 mm | 20 ms | 31 |
| Lp Nd:YAG [39] | 1064 nm | 10 W | N/A | N/A | 17 |
| Lp Nd:YAG [40] | 1064 nm | 3–50 W | N/A | N/A | 10 |
| Lp Nd:YAG [41] | 1064 nm | 8–10 W | N/A | N/A | 10 |
| Lp Nd:YAG [42] | 1064 nm | 20–30 W | N/A | 0.5–1 s | 9 |
| Lp Nd:YAG [43] | 1064 nm | 150–670 J | N/A | N/A | 6 |
| Alexandrite [44] | 755 nm | 60 J/cm2 | 8 mm | 3 ms | 4 |
| Diode [45] | 800 ± 10 nm | 8–13 W | N/A | N/A | 158 |
| Diode [46] | 800 ± 10 nm | 3–5 W | N/A | N/A | 3 |
| KTP [47] | 532 nm | 1.5 W | N/A | N/A | 7 |
| Dual PDL and Lp Nd:YAG [48] | 595 nm (PDL 1) | 8–10 J/m2 | 10 mm | 10 ms | 30 |
| 1064 nm (Nd:YAG 1) | 35–70 J/m2 | 10 mm | 15 or 20 ms | ||
| 595 nm (PDL 2) | 5–10 J/m2 | 7 mm | 10 ms | ||
| 1064 nm (Nd:YAG 2) | 50–100 J/m2 | 7 mm | 15 or 20 ms | ||
| Lp Nd:YAG and KTP [49] | 1064 nm (Lp Nd:YAG) 532 nm (KTP) | N/A | N/A | N/A | 23 |
| CO2 [50] | N/A | 2 W | N/A | N/A | 5 |
| Lp Nd:YAG [51] | 1064 nm | 15–20 W | N/A | 0.5–1 s | 4 |
| Lp Nd:YAG laser [52] | 1064 nm | 18–30 W | N/A | 0.5–1 s | 19 |
| 1064 nm | 110 J/cm2 | N/A | 0.15 ms and 1.0 Hz | ||
| Lp Nd:YAG and sclerotherapy [53] | N/A | 18–25 W | N/A | N/A | 8 |
| Diode [54] | 980 nm | 1.5–4 W | N/A | 1 min | 4 |
| Lp Nd:YAG [55] | N/A | 80–240 J | N/A | 1–29 min | 45 |
| Lp Nd:YAG and CO2 [56] | N/A | N/A | N/A | N/A | 3 Nd:YAG and 6 CO2 |
| Diode [57] | 808 nm | 4.5 W | 0.00125 cm2 | 25 ms | 3 |
Sofos et al. [35] reported on 59 patients with VMs treated with Lp Nd:YAG, where lip and oral mucosal lesions responded most favorably, whereas those on the extremities had high recurrence rates (26%) and more complications (20%). Sarig et al. [36] discussed 56 VMs treated with continuous wave (CW) or Lp Nd:YAG, with a median of 3.25 treatment sessions and a mean follow‐up of 5 years. Approximately 72% demonstrated excellent improvement following laser. VMs located on the face responded better than acral sites [36].
Alcántara‐González et al. [48] discussed the use of dual PDL and Lp Nd:YAG for 17 cutaneous and 13 mucosal VMs, most involving the head/neck. Mucosal VMs responded better than cutaneous VMs but were more likely to develop significant postoperative edema [48]. Although this approach demonstrated improvement in VM appearance, complete resolution was seen only in 23.33% of patients [48].
Eichenfield et al. [49] documented a series of 23 patients with capillary‐venous and VMs treated with Lp Nd:YAG to target deeper vessels followed by the potassium titanyl phosphate (KTP) laser for superficial lesion components. Improvements in color, texture, and elevation were reported in 50–75% using a blinded physician evaluator.
Spradley et al. [55] reported a series of 45 patients treated over 12–18 months with Lp Nd:YAG for cutaneous VMs; 72% improved based on photographic review, but complete resolution was rare and noted in < 10% of patients. Complications included pain, blistering, bleeding, and dyspigmentation.
4.1. Author Pearls/Pitfalls
Laser is not the treatment of choice for large VMs but can be utilized as adjuvant therapy, particularly on the head/neck. The greatest risk is for secondary scarring from longer wavelength modalities (alexandrite and Lp Nd:YAG), and therefore conservative settings are recommended. A longer PD of 20–80 ms should be considered based on the predictive larger size of the vasculature, and pre‐treatment ultrasound may help to quantify relative vessel size. Because of the limited depth of even longer wavelength lasers, deeper VMs (> 5–6 mm) without a superficial component are unlikely to respond well. Endpoints in VMs post laser should include slight graying of the tissue without true purpura but can take longer to appreciate with deeper penetrating lasers (at least several minutes). For this reason, treatment of smaller areas or “test spots” should be considered. Deep purpura raises significant concern for tissue damage and increases the risk for ulceration and necrosis. Some surgeons report a “pop” when the laser pulse is emitted on a VM, indicating ejection of blood from the vasculature, but this is an inconsistent endpoint. Other warning endpoints including dermal contraction, positive Nikolsky sign, true purpura, or skin vesiculation or “bubbling” suggest tissue overheating and increased risk for ulceration and scarring [58]. Due to a narrow therapeutic index between benefit and risk to the skin, we recommend starting with conservative settings, closely evaluating endpoints post‐laser, and increasing laser parameters conservatively. See Figure 3 for consideration of parameters for VAs composed primarily of deoxygenated hemoglobin. In addition, patients on systemic therapy with sirolimus or alpelisib, we would pursue shared decision making with families but suggest discontinuation of therapy a few days prior to treatment, and then for 5–7 days following laser. Delayed ulceration after combined PDL and topical sirolimus therapy has been reported for PWB, and we presume that both topical and systemic therapy could delay wound healing [59]. Patients with PiK3CA‐related overgrowth syndrome (PROS) seem to be at higher risk of scarring from surgical interventions, but this has not been reported for PiK3CA‐related VMs [60].
FIGURE 3.

Consideration of parameters for treatment of vascular lesions composed of predominantly deoxyhemoglobin (venous malformations, glomuvenous malformations).
5. Glomuvenous Malformations (GVMs)
Cutaneous GVMs present at birth or later in life as pink or bluish‐purple papules or plaque‐like lesions [61] that often develop a cobblestone or hyperkeratotic surface or both [62]. GVMs are more likely than VMs (except VVMs) to demonstrate a hyperkeratotic, cobblestone‐like appearance and cannot be emptied by compression, unlike VMs [62]. Like VMs, GVMs are composed predominantly of deoxygenated hemoglobin. GVMs are painful to palpation and thus treatment may be pursued for pain management as well as restorative outcomes [63]. Laser studies of GVMs were limited to two case series and one retrospective cohort study (Table 5) [18, 61, 63]. The quality of the literature was low.
TABLE 5.
Glomuvenous malformation laser type and parameters.
| Laser type | Wavelength | Power/fluence | Spot size | Pulse duration | Patients treated |
|---|---|---|---|---|---|
| Lp Nd:YAG [18] | 1064 nm | 90.7 J/cm2 | N/A | N/A | 8 |
| Lp Nd:YAG [63] | 1064 nm | 30–120 J/cm2 | 12 mm | 3 ms | 5 |
| 1064 nm | 100 J/cm2 | 5 mm | 30 ms | ||
| Dual PDL and Lp Nd:YAG [61] | 595 nm (PDL 1) | 6–10 J/cm2 | 10 mm | 10 ms | 17 |
| 1064 nm (Nd:YAG 1) | 30–70 J/cm2 | 10 mm | 15 ms | ||
| 595 nm (PDL 2) | 6–10 J/cm2 | 7 mm | 10 ms | ||
| 1064 nm (Nd:YAG 2) | 50–70 J/cm2 | 7 mm | 15 ms |
Murthy et al. [63] used Lp Nd:YAG lasers for five patients with cutaneous GVMs of the extremities, neck, trunk, and genitalia. Aesthetic results ranged from good to excellent based on reviewer assessment, with blistering on one patient [63]. Moreno‐Arrones et al. [61] theorized that sequential treatment with PDL followed by Lp Nd:YAG would maximize Lp Nd:YAG impact via generation of methemoglobin from the PDL pulse, thereby reducing the need for higher fluences and limiting complications. This combined technique was used for GVM of the face, neck, arm, leg, groin, or back in 17 patients, with nearly all patients reporting significant improvement.
5.1. Author Pearls/Pitfalls
Smaller, localized GVMs often respond best to complete surgical excision, particularly given the pain caused by these lesions. Sclerotherapy can result in ulceration because of the superficial nature of GVM. However, for multifocal or segmental lesions, laser can be a treatment of choice. Such lesions respond very well to either Lp Nd‐YAG or Lp alexandrite, with nearly immediate reduction in patient‐reported pain, which is often the primary indication for treatment. As with most laser modalities, serial treatments are invariably required. We suggest a larger spot size (10–15 mm) for bigger lesions, which will decrease scatter, with a PD of 20–30 ms matched to the medium‐anatomic size of the vasculature. Similar to VMs, clinical endpoints can take longer to evolve and include slight tissue graying without purpura. Epidermal change, dermal contraction, or tissue whitening are warning endpoints that suggest overheating of tissue.
6. Arteriovenous Malformations (AVM)
AVMs are high‐flow, congenital lesions that result from irregular direct connections between arteries and veins and can produce shunting. AVMs can result in high outflow cardiac failure and life‐threatening hemorrhage with rupture [19]. Most AVMs are mosaic, with a variety of variants including MAP2K1, KRAS, and BRAF variants reported [11, 64]. A smaller proportion are inherited via autosomal dominant inheritance secondary to germline RASA1 or EPHB4 variants. Data supporting laser treatment of AVMs included three case series which met our inclusion criterion (Table 6) [65, 66, 67], with low quality of evidence.
TABLE 6.
Arteriovenous malformation laser type and parameters.
| Laser type | Wavelength | Power/fluence | Spot size | Pulse duration | Patients treated |
|---|---|---|---|---|---|
| PDL [65] | 595 nm | 7–7.5 J/cm2 | 10 mm | 0.5 ms | 5 |
| Dual PDL and Lp Nd:YAG [66] | 595 nm (PDL) | 7–9 J | 7 mm | 10 ms | 26 |
| 1064 nm (Lp Nd:YAG) | 40–60 J | 7 mm | 15 ms | ||
| Dual PDL and Lp Nd:YAG [67] | 595 nm (PDL) | 7–10 J/cm2 | 7–10 mm | 10 ms | 5 |
| 1064 nm (Lp Nd:YAG) | 60–100 J/cm2 | 7–10 mm | 15 ms | ||
| 755 nm (Lp alexandrite) | 20–23 J/cm2 | 12.5 mm | 20 ms |
High‐flow vascular CMs in 5 patients with genetically confirmed CM‐AVM were treated with PDL, with excellent responses (75%–100%) reported for four patients over 1 year of follow‐up. In this cohort, two patients experienced sequelae of crusting and blistering [65]. Hereditary hemorrhagic telangiectasia (HHT) produces high‐flow telangiectasias, characteristically on the head/neck region. Sequential use of PDL followed by Lp Nd:YAG for 26 patients with telangiectasias of the face, ear, lips, and tongue in the setting of known HHT, was reported with minor complications of transient edema and pain for a few days and approximately 96% satisfaction [66].
6.1. Author Pearls/Pitfalls
Tissue injury can activate dormant AVMs, and these risks must be discussed with patients prior to therapy. High‐flow AVMs harbor an increased risk for poor response to laser and ulceration. Laser treats the cutaneous portion of these VAs only, so imaging should guide consideration of treatment based on lesional depth, particularly in head/neck AVMs. Lasers should be reserved for superficial lesions, which can be targeted by the wavelength chosen. We suggest conservative settings (with relatively low fluence, particularly when used with a short PD of 0.45 or 1.5 ms) in combination with other approaches, such as intralesional bleomycin, glue embolization, surgical resection, or medical therapy. Patients on systemic therapy with MEK inhibitors are at increased risk for hemorrhage and impaired wound healing. The half‐life of selumetinib and trametinib, the most common MEK inhibitors used for AVMs, ranges from 8 h to 4 days, respectively. In cases where laser is deemed to be helpful, we suggest considering a 1–2‐week holiday both pre‐ and post‐laser treatment to facilitate appropriate wound healing.
7. Verrucous Venous Malformations
VVM are composed of dilated capillaries and veins within the dermis that occasionally extend into the subcutaneous tissue [11]. They often present at birth or early childhood [11]. VVMs are commonly seen on the extremities, with fewer presenting on the trunk, axilla, and buttocks [11]. Literature for VVMs was sparse, with a single case series and two retrospective cohort studies (Table 7) [63, 64, 68], and low‐quality evidence.
TABLE 7.
Verrucous venous malformation laser type and parameters.
| Laser type | Wavelength | Power/fluence | Spot size | Pulse duration | Patients treated |
|---|---|---|---|---|---|
| Single or Dual Lp Nd:YAG [63] | 1064 nm (Lp Nd:YAG 1) | 40–125 J/cm2 | 12 mm | 3 ms | 5 |
| 1064 nm (Lp Nd:YAG 2) | 90–200 J/cm2 | 5 mm | 30 ms | ||
| CO2 continuous wave (CW), PDL, and dual PDL‐Lp Nd:YAG [64] | 10,600 nm (CO2) | 10–30 W | N/A | N/A | 8 |
| 595 nm (PDL) | 10–12 J/cm2 | 7 mm | 2 ms | ||
| 595 nm (dual PDL) | 10 J/cm2 | 7 mm | 10 ms | ||
| 1064 nm (dual Lp Nd:YAG) | 50–100 J/cm2 | 7 mm | 15 ms | ||
| CO2, PDL, argon, and surgical excision [68] | N/A | N/A | N/A | N/A |
2 (PDL) 2 (CO2 and PDL) 2 (CO2 and argon) 1 (argon) |
Murthy et al. [63] utilized Lp Nd:YAG alone to treat five patients with VVMs with poor to good post‐treatment assessments and one ulceration complication. Although VVM appearance did not significantly improve, quality of life did improve by patient report. In addition, treatment was shown to reduce bleeding, oozing, and crusting from the acanthotic epidermis [63].
Segura Palacios et al. [64] used a combination of CO2, PDL, or dual PDL‐Nd:YAG for VVMs located on extremities for eight patients. Dual PDL‐Nd:YAG was best for superficial and deep vascular lesions, whereas CO2 lasers successfully treated hyperkeratotic regions, and PDL alone only prevented hyperkeratosis of early superficial VVMs. On a 1–10 scale, patient satisfaction ranged from 8 to 10, indicating an overall successful treatment response.
7.1. Author Pearls/Pitfalls
VVMs can be difficult to treat and often respond poorly to lasers. In our experience, ablative CO2 has been most effective in treating the hyperkeratotic portions of VVMs. Lp Nd:YAG or Lp alexandrite can be considered judiciously for flatter lesions, although conservative settings are recommended because of the risk of ulceration. Surgery is recommended for VVMs with ulceration or bleeding. Many VVMs are negative by next generation sequencing (except MAP3K3) [64], suggesting that undiscovered genetic variability could play a role.
8. Limitations
Success of laser therapy is very dependent on the type of VA, its location, and depth. Superficial, thin, and circumscribed lesions respond better to laser, whereas deep seated lesions may require interstitial/intralesional laser therapy [69]. The laser literature was low quality across all VAs, although most studies demonstrated few complications when used in expert hands. More robust data is needed to advance the field.
9. Conclusions
Laser can be safely added to the armamentarium for treatment of complex VAs beyond PWBs. The cutaneous portion of microcystic LMs, mucosal VMs, and GVMs likely respond best to lasers. A multi‐disciplinary approach, including IR, oncology, otorhinolaryngology, head/neck, and plastic surgery, provides the best assessment of the role of laser in treatment, particularly when multi‐modal management is utilized. Advancement in the mosaic genetic nature of most VAs has facilitated the advent of targeted therapy, which can be safely combined with laser, with a drug holiday when feasible before and immediately after laser surgery.
Author Contributions
Kevin V. Thomas: conception and design of the project, performed literature review, drafted and revised the paper, final approval of submitted version. Todd Le: critical revision of the paper, final approval of submitted version. Feben Messele: critical revision of the paper, final approval of submitted version. Catharine B. Garland: critical revision of the paper, final approval of submitted version. Eric J. Monroe: critical revision of the paper, final approval of submitted version. Denise Metry: critical revision of the paper, final approval of submitted version. Yakir Levin: critical revision of the paper, final approval of submitted version. Kristen M. Kelly: critical revision of the paper, final approval of submitted version. Lisa M. Arkin: conception and design of the project, supervised literature review, critical revision of the paper, final approval of submitted version.
Conflicts of Interest
Dr. Eric J. Monroe: Consultant for Biogen, Guerbet, Vector Surgical and Inari. Dr. Denise Metry: Author royalties from UpToDate. Consultant for Verrica Pharmaceuticals. Dr. Kristen M. Kelly: Research funding from Lutronic FDZJ and Michaelson Diagnostics. Cutera and Sciton have provided equipment to our clinic. Consultant for Sciton, Lutronic and Primus Pharmaceutics. Dr. Lisa M. Arkin: PI—Amgen, Eli Lily. Candela—previous equipment (not fees). Consulting—Sanofi/Regeneron, Merck, NobelPharma. The other authors declare no conflicts of interest.
Thomas K. V., Le T., Messele F., et al., “Adding to Your Tool Box: Laser Therapy for Vascular Anomalies,” Pediatric Dermatology 42, no. 4 (2025): 716–727, 10.1111/pde.15991.
Funding: The authors received no specific funding for this work.
Data Availability Statement
Data sharing is not applicable to this article as no new data were created or analyzed in this study.
References
- 1. Mulliken J. B. and Glowacki J., “Hemangiomas and Vascular Malformations in Infants and Children: A Classification Based on Endothelial Characteristics,” Plastic and Reconstructive Surgery 69, no. 3 (1982): 412–422, 10.1097/00006534-198203000-00002. [DOI] [PubMed] [Google Scholar]
- 2. Mäkinen T., Boon L. M., Vikkula M., and Alitalo K., “Lymphatic Malformations: Genetics, Mechanisms and Therapeutic Strategies,” Circulation Research 129, no. 1 (2021): 136–154, 10.1161/circresaha.121.318142. [DOI] [PubMed] [Google Scholar]
- 3. Luks V. L., Kamitaki N., Vivero M. P., et al., “Lymphatic and Other Vascular Malformative/Overgrowth Disorders Are Caused by Somatic Mutations in PIK3CA,” Journal of Pediatrics 166, no. 4 (2015): 1048–1054, 10.1016/j.jpeds.2014.12.069. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4. Piacitelli A. M., Jensen D. M., Brandling‐Bennett H., et al., “Characterization of a Severe Case of PIK3CA‐Related Overgrowth at Autopsy by Droplet Digital Polymerase Chain Reaction and Report of PIK3CA Sequencing in 22 Patients,” American Journal of Medical Genetics. Part A 176, no. 11 (2018): 2301–2308, 10.1002/ajmg.a.40487. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5. Limaye N., Kangas J., Mendola A., et al., “Somatic Activating PIK3CA Mutations Cause Venous Malformation,” American Journal of Human Genetics 97, no. 6 (2015): 914–921, 10.1016/j.ajhg.2015.11.011. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6. Soblet J., Kangas J., Nätynki M., et al., “Blue Rubber Bleb Nevus (BRBN) Syndrome Is Caused by Somatic TEK (TIE2) Mutations,” Journal of Investigative Dermatology 137, no. 1 (2017): 207–216, 10.1016/j.jid.2016.07.034. [DOI] [PubMed] [Google Scholar]
- 7. Brouillard P., Boon L. M., Mulliken J. B., et al., “Mutations in a Novel Factor, Glomulin, Are Responsible for Glomuvenous Malformations (‘Glomangiomas’),” American Journal of Human Genetics 70, no. 4 (2002): 866–874, 10.1086/339492. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8. Couto J. A., Huang A. Y., Konczyk D. J., et al., “Somatic MAP2K1 Mutations Are Associated With Extracranial Arteriovenous Malformation,” American Journal of Human Genetics 100, no. 3 (2017): 546–554, 10.1016/j.ajhg.2017.01.018. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9. Al‐Olabi L., Polubothu S., Dowsett K., et al., “Mosaic RAS/MAPK Variants Cause Sporadic Vascular Malformations Which Respond to Targeted Therapy,” Journal of Clinical Investigation 128, no. 4 (2018): 1496–1508, 10.1172/jci98589. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10. Amyere M., Revencu N., Helaers R., et al., “Germline Loss‐Of‐Function Mutations in EPHB4 Cause a Second Form of Capillary Malformation‐Arteriovenous Malformation (CM‐AVM2) Deregulating RAS‐MAPK Signaling,” Circulation 136, no. 11 (2017): 1037–1048, 10.1161/circulationaha.116.026886. [DOI] [PubMed] [Google Scholar]
- 11. Couto J. A., Vivero M. P., Kozakewich H. P., et al., “A Somatic MAP3K3 Mutation Is Associated With Verrucous Venous Malformation,” American Journal of Human Genetics 96, no. 3 (2015): 480–486, 10.1016/j.ajhg.2015.01.007. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12. Li D., Sheppard S. E., March M. E., et al., “Genomic Profiling Informs Diagnoses and Treatment in Vascular Anomalies,” Nature Medicine 29, no. 6 (2023): 1530–1539, 10.1038/s41591-023-02364-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13. Siegel D. H., Cottrell C. E., Streicher J. L., et al., “Analyzing the Genetic Spectrum of Vascular Anomalies With Overgrowth via Cancer Genomics,” Journal of Investigative Dermatology 138, no. 4 (2018): 957–967, 10.1016/j.jid.2017.10.033. [DOI] [PubMed] [Google Scholar]
- 14. Anderson R. R. and Parrish J. A., “Selective Photothermolysis: Precise Microsurgery by Selective Absorption of Pulsed Radiation,” Science 220, no. 4596 (1983): 524–527, 10.1126/science.6836297. [DOI] [PubMed] [Google Scholar]
- 15. Geronemus R. G. and Ashinoff R., “The Medical Necessity of Evaluation and Treatment of Port‐Wine Stains,” Journal of Dermatologic Surgery and Oncology 17, no. 1 (1991): 76–79, 10.1111/j.1524-4725.1991.tb01597.x. [DOI] [PubMed] [Google Scholar]
- 16. Tran J. M., Kelly K. M., Drolet B. A., Krakowski A. C., and Arkin L. M., “Light‐Based Treatment of Pediatric Port‐Wine Birthmarks,” Pediatric Dermatology 38, no. 2 (2021): 351–358, 10.1111/pde.14503. [DOI] [PubMed] [Google Scholar]
- 17. Ash C., Dubec M., Donne K., and Bashford T., “Effect of Wavelength and Beam Width on Penetration in Light‐Tissue Interaction Using Computational Methods,” Lasers in Medical Science 32, no. 8 (2017): 1909–1918, 10.1007/s10103-017-2317-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18. Scherer K. and Waner M., “Nd:YAG Lasers (1,064 nm) in the Treatment of Venous Malformations of the Face and Neck: Challenges and Benefits,” Lasers in Medical Science 22, no. 2 (2007): 119–126, 10.1007/s10103-007-0443-0. [DOI] [PubMed] [Google Scholar]
- 19. Mulligan P. R., Prajapati H. J., Martin L. G., and Patel T. H., “Vascular Anomalies: Classification, Imaging Characteristics and Implications for Interventional Radiology Treatment Approaches,” British Journal of Radiology 87, no. 1035 (2014): 20130392, 10.1259/bjr.20130392. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20. Savas J. A., Ledon J., Franca K., Chacon A., Zaiac M., and Nouri K., “Carbon Dioxide Laser for the Treatment of Microcystic Lymphatic Malformations (Lymphangioma Circumscriptum): A Systematic Review,” Dermatologic Surgery 39, no. 8 (2013): 1147–1157, 10.1111/dsu.12220. [DOI] [PubMed] [Google Scholar]
- 21. Nammour S., Vanheusden A., Namour A., and Zeinoun T., “Evaluation of a New Method for the Treatment of Invasive, Diffuse, and Unexcisable Lymphangiomas of the Oral Cavity With Defocus CO2 Laser Beam: A 20‐Year Follow‐Up,” Photomedicine and Laser Surgery 34, no. 2 (2016): 82–87, 10.1089/pho.2015.4019. [DOI] [PubMed] [Google Scholar]
- 22. Bailin P. L., Kantor G. R., and Wheeland R. G., “Carbon Dioxide Laser Vaporization of Lymphangioma Circumscriptum,” Journal of the American Academy of Dermatology 14, no. 2 Pt 1 (1986): 257–262, 10.1016/s0190-9622(86)70030-3. [DOI] [PubMed] [Google Scholar]
- 23. April M. M., Rebeiz E. E., Friedman E. M., Healy G. B., and Shapshay S. M., “Laser Therapy for Lymphatic Malformations of the Upper Aerodigestive Tract. An Evolving Experience,” Archives of Otolaryngology—Head & Neck Surgery 118, no. 2 (1992): 205–208, 10.1001/archotol.1992.01880020111024. [DOI] [PubMed] [Google Scholar]
- 24. Lapidoth M., Ackerman L., Amitai D. B., Raveh E., Kalish E., and David M., “Treatment of Lymphangioma Circumscriptum With Combined Radiofrequency Current and 900 nm Diode Laser,” Dermatologic Surgery 32, no. 6 (2006): 790–794, 10.1111/j.1524-4725.2006.32162.x. [DOI] [PubMed] [Google Scholar]
- 25. Eliezri Y. D. and Sklar J. A., “Lymphangioma Circumscriptum: Review and Evaluation of Carbon Dioxide Laser Vaporization,” Journal of Dermatologic Surgery and Oncology 14, no. 4 (1988): 357–364, 10.1111/j.1524-4725.1988.tb03368.x. [DOI] [PubMed] [Google Scholar]
- 26. Edwards P. D., Rahbar R., Ferraro N. F., Burrows P. E., and Mulliken J. B., “Lymphatic Malformation of the Lingual Base and Oral Floor,” Plastic and Reconstructive Surgery 115, no. 7 (2005): 1906–1915, 10.1097/01.prs.0000165071.48422.a4. [DOI] [PubMed] [Google Scholar]
- 27. Wiegand S., Eivazi B., Zimmermann A. P., et al., “Microcystic Lymphatic Malformations of the Tongue: Diagnosis, Classification, and Treatment,” Archives of Otolaryngology—Head & Neck Surgery 135, no. 10 (2009): 976–983, 10.1001/archoto.2009.131. [DOI] [PubMed] [Google Scholar]
- 28. Oosthuizen J. C., Burns P., and Russell J. D., “Lymphatic Malformations: A Proposed Management Algorithm,” International Journal of Pediatric Otorhinolaryngology 74, no. 4 (2010): 398–403, 10.1016/j.ijporl.2010.01.013. [DOI] [PubMed] [Google Scholar]
- 29. Glade R. S. and Buckmiller L. M., “CO2 Laser Resurfacing of Intraoral Lymphatic Malformations: A 10‐Year Experience,” International Journal of Pediatric Otorhinolaryngology 73, no. 10 (2009): 1358–1361, 10.1016/j.ijporl.2009.06.013. [DOI] [PubMed] [Google Scholar]
- 30. Leducq S., Caille A., Barbarot S., et al., “Topical Sirolimus 0.1% for Treating Cutaneous Microcystic Lymphatic Malformations in Children and Adults (TOPICAL): Protocol for a Multicenter Phase 2, Within‐Person, Randomized, Double‐Blind, Vehicle‐Controlled Clinical Trial,” Trials 20, no. 1 (2019): 739, 10.1186/s13063-019-3767-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31. Gu Y. and Sebaratnam D. F., “Topical Rapamycin and Microcystic Lymphatic Malformations,” Journal of the American Academy of Dermatology 90, no. 1 (2024): e29–e30, 10.1016/j.jaad.2023.06.066. [DOI] [PubMed] [Google Scholar]
- 32. Nashan B. and Citterio F., “Wound Healing Complications and the Use of Mammalian Target of Rapamycin Inhibitors in Kidney Transplantation: A Critical Review of the Literature,” Transplantation 94, no. 6 (2012): 547–561, 10.1097/TP.0b013e3182551021. [DOI] [PubMed] [Google Scholar]
- 33. Seront E., Vikkula M., and Boon L. M., “Venous Malformations of the Head and Neck,” Otolaryngologic Clinics of North America 51, no. 1 (2018): 173–184, 10.1016/j.otc.2017.09.003. [DOI] [PubMed] [Google Scholar]
- 34. Del Pozo J., Martínez‐González C., Verea M. M., Fernández‐Torres R., and Fonseca E., “Venous Malformations With Lip Involvement: Palliative Treatment With Carbon Dioxide Laser Vaporization in Five Cases,” Journal of Cosmetic and Laser Therapy 11, no. 1 (2009): 14–18, 10.1080/14764170802612950. [DOI] [PubMed] [Google Scholar]
- 35. Sofos S. and Liew S. H., “The Use of Long Pulsed Neodymium‐Doped Yttrium Aluminum Garnet for the Treatment of Paediatric Venous Malformations,” Annals of Dermatology 26, no. 4 (2014): 474–477, 10.5021/ad.2014.26.4.474. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36. Sarig O., Kimel S., and Orenstein A., “Laser Treatment of Venous Malformations,” Annals of Plastic Surgery 57, no. 1 (2006): 20–24, 10.1097/01.sap.0000210632.40697.9b. [DOI] [PubMed] [Google Scholar]
- 37. Rebeiz E., April M. M., Bohigian R. K., and Shapshay S. M., “Nd‐YAG Laser Treatment of Venous Malformations of the Head and Neck: An Update,” Otolaryngology and Head and Neck Surgery 105, no. 5 (1991): 655–661, 10.1177/019459989110500504. [DOI] [PubMed] [Google Scholar]
- 38. John H. E., Phen H. S., and Mahaffey P. J., “Treatment of Venous Lesions of the Lips and Perioral Area With a Long‐Pulsed Nd:YAG Laser,” British Journal of Oral & Maxillofacial Surgery 54, no. 4 (2016): 376–378, 10.1016/j.bjoms.2015.06.014. [DOI] [PubMed] [Google Scholar]
- 39. Takamaru N., Tamatani T., Ohe G., Yamamura Y., Kudoh K., and Miyamoto Y., “Single Non‐Contact Nd: YAG Laser Irradiation Treatment for Venous Malformations in the Oral Cavity,” Journal of Oral and Maxillofacial Surgery, Medicine, and Pathology 29, no. 5 (2917): 415–419, 10.1016/j.ajoms.2017.05.010. [DOI] [Google Scholar]
- 40. Mungnirandr A., Nuntasunti W., and Manuskiatti W., “Neodymium‐Doped Yttrium Aluminium Garnet Laser Treatment of Pediatric Venous Malformation in the Oral Cavity,” Dermatologic Surgery 42, no. 7 (2016): 875–879, 10.1097/dss.0000000000000770. [DOI] [PubMed] [Google Scholar]
- 41. Eivazi B., Wiegand S., Teymoortash A., Neff A., and Werner J. A., “Laser Treatment of Mucosal Venous Malformations of the Upper Aerodigestive Tract in 50 Patients,” Lasers in Medical Science 25, no. 4 (2010): 571–576, 10.1007/s10103-010-0762-4. [DOI] [PubMed] [Google Scholar]
- 42. Gurien L. A., Jackson R. J., Kiser M. M., and Richter G. T., “Nd:YAG Laser Therapy for Rectal and Vaginal Venous Malformations,” Pediatric Surgery International 33, no. 8 (2017): 887–891, 10.1007/s00383-017-4113-4. [DOI] [PubMed] [Google Scholar]
- 43. Johnin K., Mori Y., Nakagawa S., Kobayashi K., Kageyama S., and Kawauchi A., “Venous Malformation of the Glans Penis: ‘Every‐5‐mm’ Neodymium:Yttrium‐Aluminum‐Garnet Laser Irradiation,” International Journal of Urology 28, no. 11 (2021): 1189–1191, 10.1111/iju.14662. [DOI] [PubMed] [Google Scholar]
- 44. McGill D. J. and Mackay I. R., “Alexandrite Laser Treatment of Intraoral Venous Vascular Malformations,” Plastic and Reconstructive Surgery 119, no. 6 (2007): 1962–1964, 10.1097/01.prs.0000259793.38644.9c. [DOI] [PubMed] [Google Scholar]
- 45. Limongelli L., Tempesta A., De Caro A., et al., “Diode Laser Photocoagulation of Intraoral and Perioral Venous Malformations After Tridimensional Staging by High Definition Ultrasonography,” Photobiomodulation, Photomedicine, and Laser Surgery 37, no. 11 (2019): 722–728, 10.1089/photob.2019.4635. [DOI] [PubMed] [Google Scholar]
- 46. Dell'Olio F., De Falco D., Di Nanna S., Casorelli A., and Favia G., “Diode Laser Photocoagulation of Oral Venous Malformations in Patients on Anticoagulant Therapy Without Drug Discontinuation,” Cureus 12, no. 3 (2020): e7340, 10.7759/cureus.7340. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 47. Kishimoto Y., Hirano S., Kato N., Suehiro A., Kanemaru S., and Ito J., “Endoscopic KTP Laser Photocoagulation Therapy for Pharyngolaryngeal Venous Malformations in Adults,” Annals of Otology, Rhinology, and Laryngology 117, no. 12 (2008): 881–885, 10.1177/000348940811701203. [DOI] [PubMed] [Google Scholar]
- 48. Alcántara‐González J., Boixeda P., Pérez‐García B., Truchuelo‐Díez M. T., González‐Muñoz P., and Jaén‐Olasolo P., “Venous Malformations Treated With Dual Wavelength 595 and 1064 nm Laser System,” Journal of the European Academy of Dermatology and Venereology 27, no. 6 (2013): 727–733, 10.1111/j.1468-3083.2012.04548.x. [DOI] [PubMed] [Google Scholar]
- 49. Eichenfield D. Z. and Ortiz A. E., “Efficacy and Safety of the 532‐nm KTP and Long‐Pulsed 1064‐nm Neodymium‐Doped Yttrium Aluminum Garnet Laser for Treatment of Vascular Malformations,” Dermatologic Surgery 46, no. 12 (2020): 1535–1539, 10.1097/dss.0000000000002386. [DOI] [PubMed] [Google Scholar]
- 50. Arat Y. O., Mawad M. E., and Boniuk M., “Orbital Venous Malformations: Current Multidisciplinary Treatment Approach,” Archives of Ophthalmology 122, no. 8 (2004): 1151–1158, 10.1001/archopht.122.8.1151. [DOI] [PubMed] [Google Scholar]
- 51. Crockett D. J., Meier J. D., Wilson K. F., and Grimmer J. F., “Treatment of Oral Cavity Venous Malformations With the Nd:YAG Laser Using the Underwater Technique,” Otolaryngology and Head and Neck Surgery 149, no. 6 (2013): 954–956, 10.1177/0194599813500629. [DOI] [PubMed] [Google Scholar]
- 52. Glade R. S., Richter G. T., James C. A., Suen J. Y., and Buckmiller L. M., “Diagnosis and Management of Pediatric Cervicofacial Venous Malformations: Retrospective Review From a Vascular Anomalies Center,” Laryngoscope 120, no. 2 (2010): 229–235, 10.1002/lary.20715. [DOI] [PubMed] [Google Scholar]
- 53. Gregory S., Burrows P. E., Ellinas H., Stadler M., and Chun R. H., “Combined Nd:YAG Laser and Bleomycin Sclerotherapy Under the Same Anesthesia for Cervicofacial Venous Malformations: A Safe and Effective Treatment Option,” International Journal of Pediatric Otorhinolaryngology 108 (2018): 30–34, 10.1016/j.ijporl.2018.02.005. [DOI] [PubMed] [Google Scholar]
- 54. Sarfi D., Adnane S., Haitami S., and Ben Yahya I., “Diode Laser Photocoagulation of Intraoral (and Perioral) Venous Malformations: Cases Series,” International Journal of Surgery Case Reports 88 (2021): 106436, 10.1016/j.ijscr.2021.106436. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 55. Spradley T. P., Johnson A. B., Wright H. D., Kincannon J. M., and Richter G. T., “Gentle ND:YAG Laser Therapy in the Treatment of Cutaneous Venous Malformations,” Facial Plastic Surgery & Aesthetic Medicine 23, no. 4 (2021): 289–293, 10.1089/fpsam.2020.0268. [DOI] [PubMed] [Google Scholar]
- 56. Wiegand S., Tiburtius J., Zimmermann A. P., Güldner C., Eivazi B., and Werner J. A., “Localization and Treatment of Lingual Venous and Arteriovenous Malformations,” Vascular Medicine 19, no. 1 (2014): 49–53, 10.1177/1358863x14521316. [DOI] [PubMed] [Google Scholar]
- 57. Heimlich F. V., de Arruda J. A. A., Kato C., et al., “Experience With 808‐nm Diode Laser in the Treatment of 47 Cases of Oral Vascular Anomalies,” Brazilian Oral Research 38 (2024): e025, 10.1590/1807-3107bor-2024.vol38.0025. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 58. Wanner M., Sakamoto F. H., Avram M. M., and Anderson R. R., “Immediate Skin Responses to Laser and Light Treatments: Warning Endpoints: How to Avoid Side Effects,” Journal of the American Academy of Dermatology 74, no. 5 (2016): 807–819, 10.1016/j.jaad.2015.06.025. [DOI] [PubMed] [Google Scholar]
- 59. Hobayan C. G. P., Nourse E. J., Paradiso M. M., and Fernandez Faith E., “Delayed Ulceration Following Combination Pulse Dye Laser and Topical Sirolimus Treatment for Port Wine Birthmarks: A Case Series,” Pediatric Dermatology 41, no. 1 (2024): 108–111, 10.1111/pde.15409. [DOI] [PubMed] [Google Scholar]
- 60. Steiner J. E., Cottrell C. E., Streicher J. L., et al., “Scarring in Patients With PIK3CA‐Related Overgrowth Syndromes,” JAMA Dermatology 154, no. 4 (2018): 452–455, 10.1001/jamadermatol.2017.6189. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 61. Moreno‐Arrones O. M., Jimenez N., Alegre‐Sanchez A., Fonda P., and Boixeda P., “Glomuvenous Malformations: Dual PDL‐Nd:YAG Laser Approach,” Lasers in Medical Science 33, no. 9 (2018): 2007–2010, 10.1007/s10103-018-2493-x. [DOI] [PubMed] [Google Scholar]
- 62. Boon L. M., Mulliken J. B., Enjolras O., and Vikkula M., “Glomuvenous Malformation (Glomangioma) and Venous Malformation: Distinct Clinicopathologic and Genetic Entities,” Archives of Dermatology 140, no. 8 (2004): 971–976, 10.1001/archderm.140.8.971. [DOI] [PubMed] [Google Scholar]
- 63. Murthy A. S., Dawson A., Gupta D., Spring S., and Cordoro K. M., “Utility and Tolerability of the Long‐Pulsed 1064‐nm Neodymium:Yttrium‐Aluminum‐Garnet (LP Nd:YAG) Laser for Treatment of Symptomatic or Disfiguring Vascular Malformations in Children and Adolescents,” Journal of the American Academy of Dermatology 77, no. 3 (2017): 473–479, 10.1016/j.jaad.2017.04.014. [DOI] [PubMed] [Google Scholar]
- 64. Segura Palacios J. M., Boixeda P., Rocha J., Alcántara González J., Alonso Castro L., and de Daniel Rodríguez C., “Laser Treatment for Verrucous Hemangioma,” Lasers in Medical Science 27, no. 3 (2012): 681–684, 10.1007/s10103-011-1000-4. [DOI] [PubMed] [Google Scholar]
- 65. Iznardo H., Roé E., Puig L., Vikula M., López‐Sánchez C., and Baselga E., “Good Response to Pulsed Dye Laser in Patients With Capillary Malformation‐Arteriovenous Malformation Syndrome (CM‐AVM),” Pediatric Dermatology 37, no. 2 (2020): 342–344, 10.1111/pde.14095. [DOI] [PubMed] [Google Scholar]
- 66. Cubiró X., Garcia‐Melendo C., Morales‐Munera C. E., et al., “Satisfactory Treatment of Mucocutaneous Lesions in Hereditary Hemorrhagic Telangiectasia Patients With Dual Pulsed Dye Laser and Neodymium: Yttrium‐Aluminum‐Garnet,” Dermatologic Therapy 34, no. 6 (2021): e15124, 10.1111/dth.15124. [DOI] [PubMed] [Google Scholar]
- 67. Lapresta A., Hermosa E., Boixeda P., and Carrillo‐Gijón R., “Acquired Digital Arteriovenous Malformations: Laser Treatment of an Uncommon Vascular Abnormality,” Actas Dermo‐Sifiliográficas 105, no. 5 (2014): e33–e37, 10.1016/j.ad.2013.12.019. [DOI] [PubMed] [Google Scholar]
- 68. Yang C. H. and Ohara K., “Successful Surgical Treatment of Verrucous Hemangioma: A Combined Approach,” Dermatologic Surgery 28, no. 10 (2002): 913–919, 10.1046/j.1524-4725.2002.02061.x. [DOI] [PubMed] [Google Scholar]
- 69. Ma L. W., Levi B., Oppenheimer A. J., and Kasten S. J., “Intralesional Laser Therapy for Vascular Malformations,” Annals of Plastic Surgery 73, no. 5 (2014): 547–551, 10.1097/SAP.0b013e318276daa6. [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Data Availability Statement
Data sharing is not applicable to this article as no new data were created or analyzed in this study.
